Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respire: PBF-680 in Moderate to Severe COPD
NCT05262218Phase 2Completed
- Sponsor
- Palobiofarma
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PBF-680 in chronic obstructive pulmonary disease (COPD), sponsored by Palobiofarma. Started Dec 2021; status: completed.
02
Drugs
PBF-680
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05262218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262218.